Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 2099 • 2014 ACR/ARHP Annual Meeting
Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in Psoriasis Patients Prior to Psoriatic Arthritis Onset
Remy Pollock¹, Fatima Abji¹, Husain Shakil¹, Kun Liang², Vinod Chandran¹ and Dafna D. Gladman^1,3, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a potentially destructive disease that develops in about 30% of patients with cutaneous psoriasis. Biomarkers that can predict which psoriasis…
Abstract Number: 1915 • 2014 ACR/ARHP Annual Meeting
IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R⁺/CD4⁺ and γδ T Cells
Erika Suzuki¹, Ritu Sarin², Emanual Maverakis¹ and Iannis E. Adamopoulos², ¹University of California at Davis, Sacramento, CA, ²Internal Medicine, University of California at Davis, Sacramento, CA
Background/Purpose: IL-17 is elevated in both the lesional skin and arthritic joints of psoriatic arthritis (PsA) patients. Although the IL-23/IL-17 axis has been linked with…
Abstract Number: 1851 • 2014 ACR/ARHP Annual Meeting
Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
Robert Kalb¹, David Fiorentino², Mark Lebwohl³, Craig Leonardi⁴, John Toole⁵, Kavitha Goyal⁶, Steve Calabro⁶, Wayne Langholff⁷ and Steve Fakharzadeh⁸, ¹SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, ²Dermatology, Stanford University, Redwood City, CA, ³Mount Sinai Medical Center, New York, NY, ⁴Central Dermatology, St. Louis, MO, ⁵University of Manitoba, Dermadvances Research, Winnipeg, MB, Canada, ⁶Janssen Services, LLC, Horsham, PA, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Janssen Services, LLC, Spring House, PA
Background/Purpose To report the cumulative rates of serious infections in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a multicenter, longitudinal, observational…
Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting
Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis
M. Elaine Husni¹, Danielle Brennan², WH Wilson Tang³ and Stanley Hazen³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiology, CCF, Cleveland, OH
Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity. Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…
Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
Abstract Number: 1600 • 2014 ACR/ARHP Annual Meeting
Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose . New data has emerged about the role of the inflammasome in psoriasis and psoriatic arthritis (PsA). The assembly of the inflammasome components in…
Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
David Fiorentino¹, Mark Lebwohl², Vincent Ho³, Richard Langley⁴, Kavitha Goyal⁵, Steve Fakharzadeh⁶, Steve Calabro⁵ and Wayne Langholff⁷, ¹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Mount Sinai Medical Center, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Services, LLC, Spring House, PA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…
Abstract Number: 1569 • 2014 ACR/ARHP Annual Meeting
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Alan Menter¹, Kim Papp², Gerald G. Krueger³, Matthias Augustin⁴, Francisco Kerdel⁵, Melinda Gooderham⁶, Kavitha Goyal⁷, Steve Fakharzadeh⁸, Wayne Langholff⁹, Jan Sermon¹⁰, Steve Calabro⁷ and David Pariser¹¹, ¹Baylor Research Institute, Dallas, TX, ²Probity Medical Research, Waterloo, ON, Canada, ³Dermatology, University of Utah, Salt Lake City, UT, ⁴University Clinics of Hamburg, Hamburg, Germany, ⁵University of Miami, Miami, FL, ⁶SKiN Centre for Dermatology, Peterborough, ON, Canada, ⁷Janssen Services, LLC, Horsham, PA, ⁸Janssen Services, LLC, Spring House, PA, ⁹Janssen Research and Development, LLC, Spring House, PA, ¹⁰Janssen-Cilag, Beerse, Belgium, ¹¹Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, VA
Background/Purpose We evaluated persistency (treatment longevity) of biologics in patients (pts) with psoriasis (PsO), as well as with psoriatic arthritis (PsA) in the context of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].